Quince Therapeutics Updates Pipeline Progress, Eyes Enrollment for Pivotal Phase 3 Trial in Ataxia-Telangiectasia, Reported Q1 EPS Loss of $(0.26), Cash Balance of $67.8M
Portfolio Pulse from Benzinga Newsdesk
Quince Therapeutics, Inc. (NASDAQ:QNCX) provided an update on its pipeline progress, focusing on the advancement of EryDex for ataxia-telangiectasia (A-T) and Duchenne muscular dystrophy (DMD). The company is on track to begin enrollment for a pivotal Phase 3 trial in Q2 2024, with regulatory approvals secured in the U.S. and EU. Quince reported a Q1 EPS loss of $(0.26) and a cash balance of $67.8M, expecting its cash runway to extend into 2026. The NEAT clinical trial aims to enroll approximately 86 patients, with topline results expected in the second half of 2025.
May 13, 2024 | 11:17 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Quince Therapeutics reported a Q1 EPS loss of $(0.26) and a cash balance of $67.8M, with significant progress in its pipeline, particularly for EryDex in treating A-T and DMD. The company is preparing for a pivotal Phase 3 trial and expects its cash runway to support development into 2026.
The financial results and pipeline progress indicate a stable position for Quince Therapeutics. The advancement into pivotal trials and the selection of DMD as a second program for EryDex highlight potential growth areas. However, the reported loss and the inherent risks of clinical trials introduce uncertainty, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100